Recent Finacing
Recent Raise
Celtaxsys is a clinical-stage drug developer of once-daily oral LTA4H inhibitors (acebilustat/CTX-4430) targeting neutrophil-driven inflammation in cystic fibrosis and acne; lead candidate in Phase 2b.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors